Day: April 26, 2025

– Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C – – 58.3% of patients showed durable complete responses by K-M at 24 months – – 97.3% of all treated patients remained free from progression to MIBC at 24 months– – 91.6% of responders remained cystectomy-free at 24 months – – No Grade 3 or greater treatment-related adverse events or deaths reported – – Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M – – Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025 – IRVINE, Calif., April 26, 2025 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on the future of cancer vaccines and their potential to reshape cancer immunotherapy (session #ED59). The session included presentations of key developments...

Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government’s call for vaccine supply of IXCHIQ® in La Reunion1 as the island is going through a major chikungunya outbreak with ~ 40,000 confirmed cases since the beginning of 20252. The authorities initially prioritized vaccination of adults aged 65 and over, especially...

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025 Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ETNEW YORK, April 26, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated results from its ongoing Phase...

VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) — A.I.S. Resources Limited (TSXV: AIS, OTC- PINK: AISSF) (“AIS” or the “Company”) announces the Company has closed its non-brokered private placement of 1,232,417 units (“Units”) at a price of $0.035 per unit for gross proceeds of $43,135 (the “Private Placement”). Each Private Placement Unit consists of one common share and one transferable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of 2 years from the closing date of the offering at a price of $0.05 per common share. Closing of the Private Placement is subject to final acceptance by the TSX Venture Exchange. All securities issued in connection with the Private Placement will be subject to a four-month hold period from the closing date under...